Medtech used to operate on a simpler commercial assumption. Find the physician who believed in the product, equip that physician with the right evidence, and let clinical advocacy pull the product into the institution.
That model was never perfect, but it worked often enough that many companies built their launch strategy around it. The physician champion was treated as the center of gravity, and the rest of the organization was expected to follow once the clinical case was strong enough.
That world is largely gone.
Today, the decision to adopt a medical technology rarely belongs to one person. It moves through a value analysis process where clinical, financial, operational, and administrative stakeholders all have influence, but few have unilateral authority.
This creates a paradox that many medtech companies underestimate. Nobody has buying power because everybody has buying power.
The physician may still recognize the clinical value. The nurse may understand the workflow implications better than anyone. Supply chain may see contract complexity. Finance may question the economic case. Infection prevention, IT, quality, education, and executive leadership may each see a different type of risk.
None of those stakeholders may be the final decision maker, but any one of them can slow the process, reshape the conversation, or quietly weaken momentum. In the value analysis environment, influence is distributed, and distributed influence changes the nature of adoption.
This is why the old commercial playbook often breaks down. A product can have a strong clinical champion and still fail to move. It can have compelling evidence and still stall. It can solve a real problem and still be rejected because the organization does not experience the problem in the same way the manufacturer describes it.
At TCX, we see this reality every day in our outreach. We can reach people we do not know, start conversations with stakeholders who are not actively looking for us, and surface perspectives that would otherwise remain invisible to the manufacturer.
That should raise an important question for medtech leaders. If we can get to you without knowing you, what do you think we can do with a network of 20,000+ healthcare experts?
The point is not simply access. The point is that the market is reachable, but only if you understand that influence no longer sits in one obvious place.
A manufacturer may believe the buyer is the physician, the department head, or the executive sponsor. In reality, the buying process is often shaped by a wider set of people who may never appear on the sales forecast but still have the ability to change the outcome.
The work, then, is no longer simply to persuade the most influential clinician. The work is to understand the buying ecosystem before the product enters it.
Who has to believe the product is worth the disruption? Who inherits the training burden? Who carries the cost? Who is accountable if the workflow does not change? Who has enough influence to stop the decision without ever being named as the decision maker?
These questions matter because adoption is not a moment. It is a sequence of permissions.
When medtech companies treat these groups as secondary audiences, they misread the market. They assume the sale is clinical when the decision is organizational.
That does not mean the clinician champion no longer matters. It means the champion is no longer enough.
The next generation of medtech strategy has to reflect this reality. Companies must qualify the market as carefully as they qualify the product. They must understand not only whether the device works, but whether the institution can say yes to the change the device requires.
In a value analysis world, the question is not simply, “Who is the buyer?”
The better question is, “Who has the power to make this harder?”
That is where adoption is won or lost.